Switzerland· 66831003
Mavenclad 10 mg, Tabletten
A cladribine product containing cladribinum, registered in Switzerland by Merck (Schweiz) AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Cladribine is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AA40 (cladribine), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Cladribine · ATC L04AA40
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of cladribine costs, country by country.
Normalised to the WHO defined daily dose (0.34 mg), the median price runs from $0.048 in France to $90.83 in Switzerland — a ×1908 gap.
- Switzerland: $90.83 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Cladribine · price per daily dose (0.34 mg)
USD · FX 28 Sept 2026
- CH Switzerland$90.83
- FR France$0.048
The record
At a glance
Swissmedic (Switzerland)- Active substance
- cladribinum
- Manufacturer
- Merck (Schweiz) AG
- Country
- Switzerland (CH)
- ATC code
- L04AA40
- ATC class
- Cladribine
- Defined daily dose
- 0.34 mg, O
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680668310036Blist 6 StkCHF 11367.4
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
409 interactions on record for cladribine.
Graded by severity as the source publishes them — 326 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Cladribine · interactions on record
409 records
- 326 severe
- 79 moderate
- 4 info
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Cladribine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaMAVENCLADMerck Europe B.V., Amsterdam
- United StatesCladribineApotex Corp.
- FinlandMAVENCLADMerck Europe B.V.
- NorwayMavencladMerck Europe B.V.
- IcelandMavencladMerck Europe B.V.*
- NetherlandsMavenclad 10 mg tablettenMerck Europe B.V.
- PolandMavencladMerck Europe B.V.
- SwedenMAVENCLAD 10 mg TablettMerck Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 23 EEA countries. Names it is sold under:
- Austria · Leuject
- Belgium · Leustatin
- Bulgaria · Леуджект
- Czechia · Leuject
- Germany · Leustatin
- Spain · Leustatin
- Finland · Leuject
- France · Leustatine
- United Kingdom (Northern Ireland) · Cladribine Zentiva, Leustat
- Greece · Leustatin
- Croatia · Leuject
- Hungary · Leuject
- Iceland · Mavenclad
- Italy · Leustatin
- Liechtenstein · Mavenclad
- Luxembourg · Leustatin
- Netherlands · Leustatin
- Norway · Leuject, Mavenclad
- Poland · Biodribin, Leuject
- Portugal · Cladribina Generis, Leustatin
- Romania · Leuject
- Sweden · Leuject
- Slovenia · Leuject
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/df053b22-41c6-4dfb-a385-02e54dbb4900 GET /v1/drugs/df053b22-41c6-4dfb-a385-02e54dbb4900?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "cladribinum 10 mg",
"valid_from": "2023-01-01",
"limitations": "[{\"description\":\"<!DOCTYPE html>\\n<html>\\n<head></head>\\n<body>\\n<p><strong><em>Aktive schubförmige remittierende Multipler Sklerose (aktive RRMS)<br></em></strong><em>Mavenclad wird vergütet für die Behandlung von erwachsenen Patienten mit aktiver schubförmig remittierender Multipler Sklerose (MS), definiert durch klinische oder bildgebende Befunde. Behandlung durch einen Facharzt der Neurologie.</em></p>\\n</body>\\n</html>\",\"costApproval\":null,\"indication\":\"20873.01\",\"isNew\":true,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-09-01\"},{\"description\":\"<!DOCTYPE html>\\n<html>\\n<head></head>\\n<body>\\n<p><strong>Hochaktive schubförmige remittierende Multipler Sklerose (hochaktive RRMS)<br></strong>Mavenclad wird vergütet zur Behandlung von erwachsenen Patienten mit hochaktiver schubförmig remittierender Multipler Sklerose (MS) definiert durch klinische oder bildgebende Befunde.</p>\\n<ul>\\n<li style=\\\"list-style: none;\\\">\\n<ul>\\n<li>Bei Patienten mit hoher Krankheitsaktivität trotz Behandlung mit einer krankheitsmodifizierenden Therapie (in der Regel während mindestens 6 Monaten), oder</li>\\n<li>Bei therapienaiven Patienten richtet sich die Vergütung nach aktuell geltenden klinischen Leitlinien wie der DGN.</li>\\n</ul>\\n</li>\\n</ul>\\n<p>Behandlung durch einen Facharzt der Neurologie mit zeitlichem Zugang zu MRI.</p>\\n</body>\\n</html>\",\"costApproval\":null,\"indication\":\"20873.02\",\"isNew\":true,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-09-01\"}]",
"galenic_form": "Tabl 10 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2019-06-01",
"self_retention_pct": 10
}See everything about cladribine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.